AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11722966 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Number of subjects: 30
Study 11722966 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk (200 mL twice daily for 3 wk)
Number of subjects: 30
Study 11722966 — intervention group
Group type: COMPARATOR
Intervention: Low-fat milk (during stage 3)
Number of subjects: 30
Study 31454802 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g omega-3 fatty acids (1,840 mg eicosapentaenoic acid and 1,520 mg docosahexaenoic acid) a day for 4 weeks
Number of subjects: 20
Study 30138162 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach
Number of subjects: 66
Study 30138162 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 66
Study 27168479 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based activity break led by teachers (5-min activity break three times per day for 12 weeks)
Number of subjects: 120
Study 27168479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no activity break)
Number of subjects: 120
Study 24442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b monotherapy for 24 weeks (1.5 μg/kg/week)
Number of subjects: 130
Study 24442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b monotherapy for 12 weeks (1.5 μg/kg/week)
Number of subjects: 130
Study 24442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN alpha‐2b in combination with RBV for 12 weeks (10.6 mg/kg/day)
Number of subjects: 130
Study 24442928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall SVR rate
Number of subjects: 130
Study 22291438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (3.0 mg/kg infusion for 10 min)
Number of subjects: 54
Study 22291438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant (2.0 mg/kg infusion if AFL or AF persisted)
Number of subjects: 54
Study 22291438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22291438 — intervention group
Group type: EXPERIMENTAL
Intervention: Vernakalant
Number of subjects: 54
Study 20297861 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 5096
Study 20297861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5096
Study 17937943 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal mucosa dorsal onlay urethroplasty
Number of subjects: 55
Study 17937943 — intervention group
Group type: COMPARATOR
Intervention: Penile skin flap dorsal onlay urethroplasty
Number of subjects: 55
Study 16555564 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL of contrast material with 30 mL of saline flush (group B)
Number of subjects: 88
Study 16555564 — intervention group
Group type: EXPERIMENTAL
Intervention: 85 mL of contrast material with 30 mL of saline flush (group C)
Number of subjects: 88
Study 16555564 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of contrast material alone (group A)
Number of subjects: 88
Study 12473052 — intervention group
Group type: EXPERIMENTAL
Intervention: ENP-led care (n = 99)
Number of subjects: 199
Study 12473052 — intervention group
Group type: COMPARATOR
Intervention: SHO-led care (n = 100)
Number of subjects: 199
Study 10728182 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (12 weekly sessions of minimal acupuncture and somatic moxibustion-acupuncture associated with auriculopuncture)
Number of subjects: 40
Study 10728182 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weekly sessions)
Number of subjects: 40
Study 7852511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride
Number of subjects: 8
Study 7852511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang II perfusion (1-4 ng/kg.min)
Number of subjects: 8
Study 7852511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride + Ang II perfusion
Number of subjects: 8
Study 7852511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7852511 — intervention group
Group type: COMPARATOR
Intervention: Placebo perfusion
Number of subjects: 8
Study 7852511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (10 mmol/day)
Number of subjects: 8
Study 1952202 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 1952202 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 6946205 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate mouthrinses
Number of subjects: 20
Study 6946205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31592915 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with topical poly-lactic acid and microneedle fractional radiofrequency (MFRF)
Number of subjects: 0
Study 31592915 — intervention group
Group type: COMPARATOR
Intervention: Microneedle fractional radiofrequency (MFRF) with normal saline (Control)
Number of subjects: 0
Study 30569273 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab (anti-CD3 monoclonal antibody)
Number of subjects: 56
Study 30569273 — intervention group
Group type: COMPARATOR
Intervention: Control group (original participants who did not receive teplizumab)
Number of subjects: 56
Study 28538639 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency Preservation and Resuscitation (EPR) initiated via an intra‐aortic flush of a large volume of ice‐cold saline solution.
Number of subjects: 20
Study 28538639 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPR intervention).
Number of subjects: 20
Study 24728533 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification with posterior chamber intraocular lens (IOL) implantation
Number of subjects: 30
Study 24728533 — intervention group
Group type: COMPARATOR
Intervention: Laser peripheral iridotomy (LPI)
Number of subjects: 30
Study 24345974 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training regimen from baseline to 16 weeks
Number of subjects: 20
Study 24345974 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining period from 16 to 32 weeks
Number of subjects: 20
Study 24345974 — intervention group
Group type: COMPARATOR
Intervention: Control group (no strength training)
Number of subjects: 20
Study 21685813 — intervention group
Group type: EXPERIMENTAL
Intervention: LEUPRO (leucine/protein/CHO/fat supplement 7.5/20/89/22 g · h(‐1))
Number of subjects: 12
Study 21685813 — intervention group
Group type: COMPARATOR
Intervention: Control (isocaloric CHO/fat 119/22 g · h(‐1))
Number of subjects: 12
Study 21685813 — intervention group
Group type: EXPERIMENTAL
Intervention: LEUPRO
Number of subjects: 12
Study 21685813 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 19261927 — intervention group
Group type: EXPERIMENTAL
Intervention: RECIST
Number of subjects: 37
Study 19261927 — intervention group
Group type: EXPERIMENTAL
Intervention: Choi criteria
Number of subjects: 37
Study 17477865 — intervention group
Group type: EXPERIMENTAL
Intervention: AS/AQ
Number of subjects: 220
Study 17477865 — intervention group
Group type: EXPERIMENTAL
Intervention: AS/SP
Number of subjects: 220
Study 17477865 — intervention group
Group type: COMPARATOR
Intervention: Molecular genotyping study
Number of subjects: 220
Study 15180735 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) alone (2.2 mg/kg)
Number of subjects: 70
Study 15180735 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) with olsalazine (0.5 g tid)
Number of subjects: 70
Study 15180735 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (AZA + olsalazine)
Number of subjects: 70
Study 11772451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin C therapy
Number of subjects: 0
Study 11772451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment that induces apoptosis and reduces cell density
Number of subjects: 0
Study 11772451 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment schedules designed to take advantage of drug-induced changes in tumor tissue composition
Number of subjects: 0
Study 9819288 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol (8 mg BD)
Number of subjects: 25
Study 9819288 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 7641724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5 micrograms kg‐1)
Number of subjects: 60
Study 7641724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg kg‐1)
Number of subjects: 60
Study 2768665 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with ADD/CD child confederates
Number of subjects: 0
Study 2768665 — intervention group
Group type: COMPARATOR
Intervention: Interaction with normal child confederates
Number of subjects: 0
Study 921868 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 99
Study 921868 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 99
Study 31119807 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment by dermatologists
Number of subjects: 392
Study 31119807 — intervention group
Group type: COMPARATOR
Intervention: Automated diagnosis algorithm
Number of subjects: 392
Study 28332984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) with a simultaneous integrated boost (SIB) of 82 Gy to regions of increased uptake on ProstaScint scans, total dose of 75.6 Gy in 42 fractions, with adjuvant hormonal therapy for intermediate- and high-risk patients.
Number of subjects: 71
Study 28332984 — intervention group
Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT) without the simultaneous integrated boost (SIB).
Number of subjects: 71
Study 28332984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT) with SIB.
Number of subjects: 71
Study 25860913 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 phone counselling sessions and 21 short message service messages for abstinence and coronary disease prevention (Experimental group, n=30)
Number of subjects: 62
Study 25860913 — intervention group
Group type: COMPARATOR
Intervention: Standard education (Control group, n=32)
Number of subjects: 62
Study 23335698 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb training (UL)
Number of subjects: 43
Study 23335698 — intervention group
Group type: COMPARATOR
Intervention: Lower limb training (LL)
Number of subjects: 43
Study 23335698 — intervention group
Group type: COMPARATOR
Intervention: Comparison of UL and LL groups
Number of subjects: 43
Study 19615769 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volume measurements (LAV(max), LAV(min)) using multi-detector computed tomography (CT)
Number of subjects: 377
Study 19615769 — intervention group
Group type: EXPERIMENTAL
Intervention: Top quartile LAV(max) and LAV(min)
Number of subjects: 377
Study 19615769 — intervention group
Group type: EXPERIMENTAL
Intervention: LA volumes added to CT finding of indeterminate stenosis
Number of subjects: 377
Study 19567208 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in combination with doxorubicin and cyclophosphamide (TAC)
Number of subjects: 0
Study 19567208 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in an unlicensed sequential regimen FEC100-T
Number of subjects: 0
Study 19567208 — intervention group
Group type: COMPARATOR
Intervention: TAC compared with FAC
Number of subjects: 0
Study 19567208 — intervention group
Group type: COMPARATOR
Intervention: FEC100-T compared with FEC100
Number of subjects: 0
Study 17178978 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment
Number of subjects: 881
Study 17178978 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment
Number of subjects: 881
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid carcinoma (PC)
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Aneuploid parathyroid carcinoma (PC)
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Diploid parathyroid carcinoma (PC)
Number of subjects: 15
Study 15369455 — intervention group
Group type: COMPARATOR
Intervention: Parathyroid adenoma (PA)
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall postoperative survival in patients with PC
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between DI and AgNOR counts
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between survival and DI
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between survival and AgNOR counts
Number of subjects: 15
Study 15369455 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between preoperative biochemical parameters and survival
Number of subjects: 15
Study 11172506 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE set with interlocking device (Group 1)
Number of subjects: 90
Study 11172506 — intervention group
Group type: EXPERIMENTAL
Intervention: CSE set with 'backeye' (Group 2)
Number of subjects: 90
Study 11172506 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-segment technique (Group 3)
Number of subjects: 90
Study 11172506 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study 11172506 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 90
Study 9883434 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG (1.2% clindamycin phosphate, 0.025% tretinoin gel)
Number of subjects: 145
Study 9883434 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin gel (0.025%)
Number of subjects: 145
Study 8533564 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 35
Study 8533564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11527111 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 150
Study 11527111 — intervention group
Group type: COMPARATOR
Intervention: Off treatment
Number of subjects: 150
Study 696747 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline 16 mg/kg/day
Number of subjects: 15
Study 696747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30607928 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPN with ischemia
Number of subjects: 0
Study 30607928 — intervention group
Group type: COMPARATOR
Intervention: RAPN without ischemia
Number of subjects: 0
Study 27049596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued-recall test on 'old' pairs
Number of subjects: 0
Study 27049596 — intervention group
Group type: COMPARATOR
Intervention: Restudy of 'old' pairs
Number of subjects: 0
Study 27049596 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued-recall test with intermixed 'new' and 'old' pairs
Number of subjects: 0
Study 24562697 — intervention group
Group type: EXPERIMENTAL
Intervention: DonJoy (DJO)
Number of subjects: 0
Study 24562697 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Care 300 (PC300)
Number of subjects: 0
Study 24562697 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Care 500 Lite (PC500L)
Number of subjects: 0
Study 24562697 — intervention group
Group type: EXPERIMENTAL
Intervention: DeRoyal T505 (DR505)
Number of subjects: 0
Study 24562697 — intervention group
Group type: EXPERIMENTAL
Intervention: All devices during rewarming period
Number of subjects: 0
Study 24187115 — intervention group
Group type: EXPERIMENTAL
Intervention: DOVE intervention (10-minute brochure-based IPV intervention and nurse home visitation)
Number of subjects: 239
Study 24187115 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 239
Study 21131142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvinorin A (doses ranged from 0.375 μg/kg to 21 μg/kg)
Number of subjects: 4
Study 21131142 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Number of subjects: 4
Study 21131142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 19032459 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐I at 1 microg/kg plus RBV for 24 weeks
Number of subjects: 55
Study 19032459 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐I at 1.5 microg/kg plus RBV for 24 weeks
Number of subjects: 55
Study 17954654 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative placement of occlusion balloons within the internal iliac arteries
Number of subjects: 11
Study 15234295 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow UV intraocular lenses (IOLs)
Number of subjects: 60
Study 15234295 — intervention group
Group type: COMPARATOR
Intervention: Ordinary UV intraocular lenses (IOLs)
Number of subjects: 60
Study 16326336 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour structured course on regional anesthesia techniques for pain management
Number of subjects: 40
Study 16326336 — intervention group
Group type: COMPARATOR
Intervention: 1-hour lecture tutorial on regional anesthesia techniques and 1 hour of bedside teaching
Number of subjects: 40
Study 12791021 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision (T)
Number of subjects: 40
Study 12791021 — intervention group
Group type: COMPARATOR
Intervention: Midline incision (M)
Number of subjects: 40
Study 9062345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous CGP 51901 (3, 10, 30, and 100 mg)
Number of subjects: 33
Study 9062345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 8473790 — intervention group
Group type: COMPARATOR
Intervention: rh‐SOD (10000 U/kg) administered through the aortic root into the coronary artery prior to reperfusion (group II)
Number of subjects: 51
Study 8473790 — intervention group
Group type: COMPARATOR
Intervention: rh‐SOD (10000 U/kg) administered into the cardiopulmonary circuit prior to reperfusion (group III)
Number of subjects: 51
Study 8473790 — intervention group
Group type: COMPARATOR
Intervention: rh‐SOD (3000 U/kg) administered into the cardiopulmonary circuit prior to reperfusion (group IV)
Number of subjects: 51
Study 2883043 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (Aldomet)
Number of subjects: 25
Study 2883043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2655822 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser sac lavage
Number of subjects: 24
Study 2655822 — intervention group
Group type: COMPARATOR
Intervention: Lesser sac drainage
Number of subjects: 24
Study 31652073 — intervention group
Group type: COMPARATOR
Intervention: Oral conjugated equine estrogens (0.45 mg/d)
Number of subjects: 727
Study 31652073 — intervention group
Group type: COMPARATOR
Intervention: Transdermal 17β‐estradiol (50 µg/d)
Number of subjects: 727
Study 31652073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 27537410 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled frequency breathing (CFB) group, breathing every 7-10 strokes
Number of subjects: 20
Study 27537410 — intervention group
Group type: COMPARATOR
Intervention: Control group, breathing every 3-4 strokes
Number of subjects: 20
Study 27537410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 25603890 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol 0.2%/LR2412 2% cream
Number of subjects: 120
Study 25603890 — intervention group
Group type: COMPARATOR
Intervention: tretinoin 0.025% cream
Number of subjects: 120
Study 24189759 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular neridronate 25 mg administered once a month for 12 months
Number of subjects: 87
Study 24189759 — intervention group
Group type: COMPARATOR
Intervention: Oral alendronate 70 mg administered once-weekly for 12 months
Number of subjects: 87
Study 24189759 — intervention group
Group type: COMPARATOR
Intervention: Oral risedronate 35 mg administered once-weekly for 12 months
Number of subjects: 87
Study 24189759 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (neridronate, alendronate, risedronate)
Number of subjects: 87
Study 21427858 — intervention group
Group type: EXPERIMENTAL
Intervention: Discectomy combined with Isobar non-fusion internal fixation (Group A)
Number of subjects: 65
Study 21427858 — intervention group
Group type: COMPARATOR
Intervention: Single discectomy (Group B)
Number of subjects: 65
Study 19865538 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (150 mg/day for 42 days)
Number of subjects: 0
Study 19865538 — intervention group
Group type: COMPARATOR
Intervention: Quercetin (1, 10, 20 micromol/L) in RAW264.7 macrophages
Number of subjects: 0
Study 19865538 — intervention group
Group type: EXPERIMENTAL
Intervention: Isorhamnetin (methylated quercetin derivative)
Number of subjects: 0
Study 19865538 — intervention group
Group type: COMPARATOR
Intervention: Quercetin-3-glucuronide (glucuronidated metabolite)
Number of subjects: 0
Study 17712236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atomoxetine (up to 3.0 mg/kg/day in study 1; up to 2.4 mg/kg/day in study 2)
Number of subjects: 247
Study 17712236 — intervention group
Group type: COMPARATOR
Intervention: Continued same-dose atomoxetine
Number of subjects: 247
Study 15070924 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated fat‐enriched ketogenic diet (POLY KD)
Number of subjects: 20
Study 15070924 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid‐enriched ketogenic diet (SAT KD)
Number of subjects: 20
Study 11605930 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 65
Study 11605930 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 65
Study 11605930 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 65
Study 11605930 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 65
Study 9677791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bennett Cascade water‐bath humidifier
Number of subjects: 45
Study 9677791 — intervention group
Group type: EXPERIMENTAL
Intervention: Fisher & Paykel servocontrolled humidifier
Number of subjects: 45
Study 9677791 — intervention group
Group type: COMPARATOR
Intervention: HME Hygrobac DAR
Number of subjects: 45
Study 8131528 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (4 g IV over 30 min)
Number of subjects: 0
Study 8131528 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.25 mg SC)
Number of subjects: 0
Study 2679244 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur tablets (200 mg theophylline anhydrous sustained-release) taken in the evening with food
Number of subjects: 0